Since mid-2025, the Weston Family Foundation has systematically moved large tranches of capital out of academic laboratories and attached them to real-world outcomes — four university teams contractually required to reach farm-scale readiness by 2028, $20 million in health “Big Bets” scaling toward the clinic, $8 million to normalize prescribed burning nationally, and $5.2 million distributed across seventeen microbiome laboratories asked to produce causal, patient-facing interventions. The Foundation’s “Spark, Shepherd, Scale” model has done what most philanthropic funders only describe: it has taken ownership of the strategy-execution gap.
What the model surfaces, at this stage of the portfolio, is a distinct class of problem. In each of the Foundation’s eight current initiatives, the binding constraint is no longer scientific or financial — it is coordinative. The science is largely knowable, the capital is committed, and the constraint owners are identifiable by name. What has not yet happened is a binding agreement among those owners about how, specifically, they will move together before the relevant clocks close: 2028 for agriculture and clinical scaling, 2030 for northern conservation, and the next fire season for prescribed burn practitioners who are trained but not yet legally authorized to act.
This brief maps eight initiatives carrying that structural signature, examines the boundary at which the Foundation’s existing convenings hand the work forward, and works through two challenges — bringing coherence to the seventeen-laboratory microbiome portfolio and turning provincial agreement on prescribed fire into a nationally recognized standard — to show what a decision-forcing process produces at each stage that sequential consultation does not. The argument is straightforward: the Foundation has supplied the capital and the science. What its boldest bets now require is a room structured to force the trade-offs that have not yet been resolved.
Over the past year, the Weston Family Foundation has done something most philanthropic funders describe in strategy documents but rarely execute: it has moved serious capital out of the laboratory and attached it to real-world outcomes. The Foundation’s “Spark, Shepherd, Scale” model now conditions large tranches of funding on whether supported ideas actually enter the world. Four university teams are contractually required to reach commercial farm-scale readiness under a hard 2028 milestone.1 A $20-million pair of health “Big Bets” is pushing biomarker science and microbiome-based nutrition toward the clinic.2 An $8-million national program is working to put prescribed fire back on the land.3 Up to $5.2 million is distributed across seventeen laboratories asked to turn microbiome correlation into causal, patient-facing intervention.4 The Foundation has also committed $10 million to next-generation Alzheimer’s diagnostics, $10 million to a soil health initiative, and $25 million to prairie grasslands stewardship. The capital is committed. The science is fundable. In most of these portfolios, the answer is largely knowable.
What remains is execution — and execution of a particular kind. In each of these initiatives, success depends on actors no single party controls: academic researchers alongside hardware suppliers and grocery buyers; Indigenous governments alongside provincial regulators and federal agencies; clinical-trial boards alongside diagnostic-lab networks and payers. The Foundation has effectively underwritten the systemic risk of getting these people to move together. That is a coordination problem, not an analytical one, and coordination problems have a different shape than the problems grantmaking is built to solve.
This distinction changes what counts as progress. A well-run grant competition identifies the strongest science and the most capable investigators. It does not, by design, require the people who must implement that science to resolve their trade-offs in a binding setting. The Weston Family Foundation is not unusual in facing this handoff — if anything, the ambition of its current portfolio throws the line between a funded strategy and a coordinated one into unusually sharp relief. The argument of this brief is simple: several of the Foundation’s boldest bets are now gated less by what is known than by whether the right constraint owners have ever been in the same room with a mandate to decide.
The venture-philanthropy turn is what makes the question urgent. When a funder distributes endowment income and measures success by the quality of the work it enables, the handoff to execution is largely someone else’s concern. When a funder conditions tranches on real-world milestones — Technology Readiness Level 8, clinical viability, recognized certification, hectares under enforceable stewardship — it has taken ownership of the coordination risk it once left downstream. The Foundation now occupies the position of the actor who must make a system work, without holding the operational levers any single actor would need to make it work alone. That is precisely the condition in which a decision-forcing process earns its place: the analysis is done, the money is committed, and what is missing is a binding agreement among people who do not report to one another.
It is worth being precise about why capital alone does not close this kind of gap. Funding removes the resource constraint, and in research that is often the dominant one. But the constraints that remain after funding is secured are relational and institutional: a provincial ministry that has not committed to recognizing a new certification, a grocery chain that has not confirmed an offtake price, a research ethics board that reads a protocol differently than its neighbour, an Indigenous government whose authority cannot be delegated to a partner. None of these constraints yields to a larger cheque. They yield to a decision that the relevant owners make together and then hold. A funder that has moved its capital to the edge of execution has, in effect, purchased a coordination problem — and coordination problems are solved by a different instrument than the one that selected the science.
Read across the Foundation’s last twelve months and a pattern emerges. The same structural conditions recur: multiple owners of the constraints, none able to mandate the others; broad agreement in principle that never hardens into binding commitments; dependence on an external “village” that must move in concert; a real deadline; and a funded strategy that has not yet converted into coordinated action. Eight current initiatives carry that signature. The tiles below name each one, the structural trap it sits in, and the recent, citable trigger that makes it live now.
On April 14, 2026, the Weston Family Microbiome Initiative named seventeen Proof-of-Principle grantees spanning oncology, neurology, maternal health, dentistry, and gastroenterology — each required to demonstrate causal intervention rather than mere observation.5 The cohort represents a deliberate maturation of the program, a move from cataloguing what dysbiosis looks like toward actively modulating it in patients. But seventeen dispersed laboratories now face the same translational walls — ethics review, patient recruitment, regulatory pathways, intellectual property, manufacturing of live biotherapeutics — with no shared structure for solving those walls once instead of seventeen times. The science is distributed; the obstacles are common.
On March 18, 2026, the Foundation introduced its 2025 Northern Conservation Program cohort: grants of $450,000 to $1.5 million to eight Indigenous-led projects — from the Dehcho’s Edéhzhíe stewardship to Ya’thi Néné’s 1.2-million-hectare protected areas in Saskatchewan — aligned to the Kunming-Montreal target of conserving 30 percent of Canada’s land and waters by 2030.6 The conservation target cannot be met top-down; it depends on Indigenous governments, Crown land-managers, industry rights-holders, and NGOs braiding Indigenous law with Western science across overlapping jurisdictions. The funding builds real capacity. What it cannot purchase is the cross-jurisdictional governance that turns protected status into enforceable stewardship.
On February 25, 2026, the Foundation and UBC Okanagan launched the $8-million Canadian Prescribed Fire Training Program — five regional hubs integrating Indigenous fire stewardship with Western science, following consecutive record wildfire seasons.7 The ecological case for prescribed burning is settled. What is not settled is who carries the liability, whose certification provinces will recognize, and how trained practitioners move from classroom preparation to a sanctioned burn on the land. The program creates capacity; it does not, on its own, create the legal and institutional recognition that lets that capacity act.
Across mid-2025 into early 2026, four Scaling-Phase teams — from the University of Guelph, Toronto Metropolitan University, Simon Fraser University, and Université Laval — each received up to $5 million and a contractual obligation to reach Technology Readiness Level 8 before a final 2028 assessment.8 Reaching that bar requires plant biologists, automation engineers, commercial growers, and retail buyers to integrate simultaneously. TMU’s award even turns on an engineered workaround for a biological failure — bees do not reliably pollinate under artificial light — illustrating how thoroughly the work has moved from theory to execution.9 With retail offtake from major grocers still unconfirmed, the risk is that the execution gap simply shifts from the laboratory to the grocery aisle.
On September 22, 2025, the Foundation awarded $10 million to Dr. Pedro Rosa-Neto at McGill University for next-generation Alzheimer’s biomarkers, and funded a Rapid Response cohort of decentralized diagnostic tools: iPad-based eye-tracking, VR memory tests, plasma p-tau-217 reference intervals across 2,500 Canadian patient samples.10 As costly therapeutics reach the market, they are of limited use without scalable diagnostics. Scaling those diagnostics requires academic labs, Health Canada, diagnostic-lab networks, primary care, and payers to align on standards and evidence thresholds that no single actor will fund or mandate alone. The unglamorous baseline work — establishing reference intervals, harmonizing laboratory protocols, integrating tools into primary care workflows — is exactly the kind of work that everyone agrees must happen and that no single party has yet owned.
The same September 2025 announcement split $20 million between two scaling projects: Rosa-Neto’s biomarker work at McGill and an Alberta–Ottawa program led by Dr. Heather Armstrong and Dr. Alain Stintzi, focused on microbiome-based precision nutrition for inflammatory bowel disease.11 Each project must marshal clinical infrastructure, regulatory clearance, vendor partnerships, and clinician adoption inside a fixed funding window. The science has been selected; the deployment system around it has not yet been assembled.
The five-year, $10-million Weston Family Soil Health Initiative aims to expand beneficial management practices across Canadian farmland, complementing the $25-million Prairie Grasslands Initiative.12 Adoption turns on individual farmers weighing short-term financial exposure — a decision that researchers, lenders, agronomists, retailers, and policymakers each influence but none can make. The agronomic evidence is not the binding constraint. The alignment of incentives across the people who surround the farmer is.
Through 2025 and 2026, the Foundation professionalized its scientific oversight, adding specialized program directors including Lauren Isaacs on the Weston Brain Institute and Marcel van de Wouw on the Microbiome Initiative, while governance and public messaging continued to emphasize purpose-driven, milestone-based impact under President Galen G. Weston and Board Chair Garfield Mitchell.13 The Foundation’s aggressive pivot to milestone-gated, venture-style funding places measurable-scale expectations alongside the non-linear pace of scientific discovery. The two registers — commercial accountability and scientific risk — benefit from an explicit framework to translate between them, so that milestone design reflects how biological and ecological discovery actually behaves rather than how financial reporting prefers it to behave.
Eight initiatives, one structure. In each, the analysis is fundable and the strategy is set; what is unresolved is whether the constraint owners will commit, together, to a single plan before the clock runs out. The signals repeat so consistently across health, conservation, and agriculture that they describe a property of the Foundation’s current model rather than a feature of any one program.
The Foundation already runs the convening instruments its field offers — calls for proposals, expert review panels, advisory committees, grantee gatherings. These do real work: they identify the strongest science, confirm where stakeholders already agree, and build high-level alignment on what the problems are. That is the job they are built for, and the Foundation does it well. The 2025 and 2026 programming cycles demonstrate the genuine sophistication of that selection work across three distinct domains simultaneously.
There is a boundary to the convening format, and it is a boundary of the format itself rather than of any organizer. A well-run symposium or advisory review assembles people to share knowledge and align at a high altitude; it is not built to force a small group of constraint owners to trade one priority against another and leave with binding, owned commitments. The people who control the real constraints — the provincial liability officer, the grocery buyer, the clinical-trial administrator, the Guardian-program lead — are rarely at the table. Senior leaders attend in their place. Agreement reached at that altitude tends to stay general. This is not a shortcoming of the Foundation’s convenings; it is a feature of the format itself, and it holds across every funding ecosystem.
The distinction is not between good convenings and bad ones. It is between two different jobs. The first job is to map a problem and agree on its causes — and a well-run grant cycle or expert panel does that efficiently. The second job is to resolve a problem: to make the specific trade-offs, assign the specific owners, and leave with commitments that bind. The second job requires a different room: smaller, more durable, populated by the people who actually hold the constraints, and structured so the meeting cannot end in a restatement of the problem. Most institutions own excellent instruments for the first job. Few have a standing instrument for the second.
The next step is that second instrument: a structured, decision-forcing process whose room is the tool. It convenes the internal team alongside the external village that controls the constraints, and runs them through a disciplined sequence — Analyze, Diverge, Converge — that ends not in a report but in a plan with named owners, resolved trade-offs, and commitments made in the room by the people who must honor them.
The sequence matters. Analyze forces a shared, honest map of the constraints and who owns each one, so the group argues from the same facts rather than from institutional assumptions about what others will or will not do. Diverge generates a wide field of options across the boundaries that map exposes — deliberately including the moves that no single actor would propose alone, because the upside belongs to the portfolio rather than to any individual party. Converge then forces the trade-offs, because a plan that does not choose is a plan that collapses on contact with execution. Two of the Foundation’s current challenges show what that sequence looks like in practice.
The following two examples walk the Analyze → Diverge → Converge sequence through the microbiome portfolio challenge and the prescribed fire national standard challenge. The intent is not to prescribe specific outcomes — those belong to the people in the room — but to show what the process surfaces at each stage that sequential consultation does not.
The Analyze stage is not a gap assessment prepared in advance and delivered to participants. It is a structured process in which the constraint owners themselves surface what each party actually controls and where the dependencies between them run.
In the Weston Family Microbiome Initiative’s Proof-of-Principle 2025 cohort, that map has a specific shape. Seventeen laboratories across oncology, neurology, maternal health, dentistry, and gastroenterology are each, independently, about to encounter the same walls: ethics-board approval, patient recruitment, the regulatory pathway from causal intervention to approved use, intellectual-property terms, and manufacturing of live biotherapeutics or fecal microbiota transplant material. What Analyze surfaces is not the existence of those walls — every principal investigator knows they exist — but who actually controls each one and where the control points are shared across the cohort.
A regulatory precedent set by one project lowers the wall for the next. A manufacturing partner qualified once can serve several projects. A data-sharing standard agreed early prevents a tangle of incompatible consent terms later. Yet the Follow-on funding structure rewards individual milestones, which makes solving anything collectively structurally unattractive. No principal investigator, optimizing for their own project, will volunteer to build shared manufacturing infrastructure or author a common evidence standard; the effort is individual and the benefit is collective. Only a forum that explicitly rewards cross-boundary thinking puts those options on the table — and only a room that includes Initiative Program Director Marcel van de Wouw, who holds the gates, can make them credible.
Analyze also does something subtler: it separates the problems that appear identical but are not. A maternal-health trial of Lactobacillus crispatus supplementation and an oncology trial of a microbiome-derived immunotherapy adjuvant both face “patient recruitment,” but the ethics, vulnerable-population safeguards, and regulatory classification differ sharply. Dr. Stefania Ronzoni’s Phase I clinical trial of vaginal microbiome modulation for preterm birth prevention and Dr. Arielle Elkrief’s work on live biotherapeutic products for lung cancer and melanoma immunotherapy share a program but not a protocol.14 Naming those differences in the room prevents a false consensus in which everyone agrees to “solve recruitment” and then discovers they meant different things. The honest map is the precondition for options that actually fit.
Dimensions of this challenge:
| Dimension | Why it cannot be solved alone |
|---|---|
| Translational regulatory pathway | One precedent set by a single project lowers the wall for the whole cohort; left to each lab, it is re-litigated seventeen times. |
| Clinical-trial ethics and recruitment | Ethics boards and patient recruitment are shared bottlenecks; vulnerable-population trials especially benefit from a common protocol rather than parallel applications. |
| Cross-portfolio IP and data terms | Without a pre-agreed template, incompatible consent and IP terms block the exchange of findings between projects at precisely the moment cross-project data becomes most valuable. |
| Manufacturing and biotherapeutic scale-up | Qualifying live-biotherapeutic and FMT manufacturing once can serve several projects; done privately it is duplicated, slow, and expensive. |
| Common causal-evidence standard | Proof generated in one disease area is only reusable if all projects agree in advance what counts as causal evidence across the clinical categories. |
| Follow-on readiness and decision gates | Advancement gates that reward only individual milestones make portfolio-level coordination structurally unattractive and collectively penalize the cohort’s strongest movers. |
With the constraints mapped and shared, the second stage generates options that cross the boundaries Analyze exposed — the kind no single laboratory would propose because no single laboratory owns the upside. Teams are deliberately constituted to mix manufacturing specialists, clinical investigators, regulatory staff, ethics-board representatives, and patient-recruitment partners who do not ordinarily share a design table. Their task is to generate options for the portfolio-scale problem, not to evaluate or defend individual project positions.
From that configuration, options emerge that bilateral conversations between the program director and individual grantees would not produce: a shared regulatory navigator engaged once on behalf of the whole cohort, lowering the burden for every project simultaneously. A common causal-evidence standard so that proof generated in the gastroenterology projects is legible to the neurology projects — and legible to Health Canada reviewers who will evaluate them in sequence. Pooled manufacturing capacity for live biotherapeutics and FMT material, so the quality systems that govern Dr. Dina Kao’s feasibility study for FMT as combination therapy for ulcerative colitis and Dr. Elkrief’s live biotherapeutic production do not need to be independently built from the ground up.15 A pre-negotiated data- and IP-sharing template that lets projects exchange findings at portfolio milestones without eroding their individual commercial position. A cross-portfolio patient-recruitment consortium connecting the maternal-health trials, the gastroenterology trials, and the oncology trials to shared patient-advocacy networks rather than requiring each lab to build those relationships independently.
The value of Diverge is breadth. The highest-value options in a competitive cohort are the least intuitive, because the competitive structure suppresses them. Only a process that explicitly rewards cross-boundary thinking will surface them consistently — and only a room that includes the program director, who controls the gates, makes them credible enough for the grantees to pursue.
The third stage forces choice. The village — the grantees, the program leadership, and the actors who control the translational walls — converges on a single 30/60/90-day plan with named owners and resolved trade-offs.
The trade-off that must be forced here is the one a competition naturally suppresses. Each principal investigator has a rational incentive to guard data, time, and intellectual property until their own milestone is secure. Converge does not wish that incentive away; it changes what advancement rewards, so that contributing a regulatory precedent or a manufacturing qualification to the cohort becomes a path to the next gate rather than a gift to a rival. That is a decision only the program director and the grantees can make together — and only once, in a setting that binds them. Made well, it converts seventeen competing timelines into one portfolio moving on a shared clock.
In the first thirty days, the cohort adopts a common causal-evidence standard and names a shared regulatory navigator. By sixty days, a manufacturing and data-sharing template is signed. By ninety days, the Follow-on funding gates are re-expressed so that cross-portfolio contribution counts toward advancement, not against it. The deliverable is not a strategy document. It is a set of commitments the people who must honor them made together.
The village that must be in the room:
| Stakeholder | Role in the problem | Why their absence stalls the solution |
|---|---|---|
| Proof-of-Principle grantees (17 PIs) | Own the science and individual milestones | Without them in one room there is no portfolio — only seventeen parallel projects each solving the same problem in isolation. |
| Initiative Program Director (Marcel van de Wouw) | Holds the cohort mandate and Follow-on gates | Absent, no one can re-express advancement rules to reward shared progress over individual competition. |
| Research ethics boards / REBs | Gate clinical work and patient recruitment | Their constraints, unsurfaced early, surface late and stall trials one project at a time rather than being resolved once for all. |
| Health Canada / regulatory advisors | Own the path to approved use | Without them, the cohort optimizes for publication rather than deployment, and regulatory walls are encountered seventeen times. |
| Manufacturing and supply partners | Produce live biotherapeutics and FMT material at scale | Absent, manufacturing scale-up is duplicated at every lab and the costliest translational wall stays private. |
| Patient recruitment and advocacy partners | Control access to clinical trial populations | Without them, even fully funded trials stall at enrollment — particularly in vulnerable-population and pediatric studies. |
This is a structural challenge Mind Meeting Group has resolved in an adjacent domain. In March 2022, the firm was engaged by NOAA’s National Environmental Satellite, Data, and Information Service (NESDIS) to work through the fragmentation of its wildfire product suite. Twenty-six participants over three days — satellite scientists, program managers, National Weather Service forecasters, an EPA director, and external power users — worked through six interconnected topics until they left with a unified product playbook, an empowered program manager, and a community-of-practice co-development model that the participants themselves had designed and committed to operate. The structural condition was the same one prescribed fire presents now: broad agreement on what mattered, real money on the table, a fast-approaching fire season, and no accountable team or shared mechanism to act.
The NESDIS engagement is instructive precisely because the obstacle was never the science. NOAA operated the most capable fire-detection satellites in the world. What it lacked was an integrated operational system and a single accountable owner, because the relevant products had been built through separate acquisition programs with their own funding lines and incentives. Agreement on priorities had been reached repeatedly across the organization and had repeatedly failed to convert into coordinated action. The room changed that by forcing the trade-offs and naming the owner. Prescribed fire now requires the same move, across a more complex institutional landscape.
The ecological case for prescribed burning is settled — decades of fire science, two consecutive record wildfire seasons, and the plain evidence of landscapes maintained under Indigenous burning practices for millennia.16 The constraints are institutional, and the Analyze stage names them precisely.
The Canadian Prescribed Fire Training Program, launched by UBC Okanagan under Dr. Mathieu Bourbonnais, has built five regional training hubs integrating Indigenous fire stewardship with Western fire science.17 What it has not yet resolved is the question that determines whether that training produces practitioners who can burn. Provinces own Crown-land liability and have not committed to recognizing the CPFTP certification. Ecologists, Indigenous knowledge keepers, Parks Canada, provincial wildfire agencies, and insurers share broad agreement in principle that prescribed burning reduces catastrophic fire risk. No single actor among them can authorize widespread adoption. Each waits for another to move first, and the result is a national training capacity that has been built and cannot yet be deployed.
Analyze makes this deadlock legible by naming who must act at each constraint. A trainer can certify a burn boss, but a province must recognize the certification. An Indigenous government holds both the fire knowledge and the territorial authority, but its role is too often treated as advisory rather than co-equal. An insurer can price the risk, but only once liability is assigned to a named party. The map does not resolve these constraints — that is Converge’s job — but it ends the ambiguity about who must act, which is the precondition for resolving them.
What Analyze also reveals is the cost of the current architecture to the practitioners it has trained. A program that invests years in building regional hubs and certifying practitioners, only to leave those practitioners legally unable to burn because provincial recognition has not been secured, is not a failure of the science or the training. It is a coordination failure — one that a decision-forcing process is designed to break.
Dimensions of this challenge:
| Dimension | Why it cannot be solved alone |
|---|---|
| National certification and curriculum standard | A certification only works if it is one standard; competing regional curricula leave practitioners unrecognized and unlicensed when they cross provincial boundaries. |
| Crown-land liability and legal authorization | Provinces own the liability; no trainer or burn boss can authorize widespread adoption without their explicit legal commitment. |
| Provincial regulatory recognition | Certification that provinces do not formally recognize leaves trained practitioners legally unable to burn on Crown land regardless of their competence. |
| Indigenous-led fire stewardship integration | Stewardship authority must be co-equal, not consultative, or the integration is nominal and the strongest knowledge base is left at the margins of implementation. |
| Insurance and risk underwriting | Unpriced, unassigned risk paralyzes every actor; a workable underwriting model is the mechanism that converts liability fear into managed authorization. |
| Cross-hub operational coordination | Five regional hubs need a shared mechanism so an approval pathway developed in one region informs and accelerates the next rather than each hub solving the same problem independently. |
With the constraint map visible and shared, Diverge generates the cross-boundary moves that no single actor would propose from their own institutional position. Teams — mixing UBCO program leads, provincial forestry officers, Indigenous fire-stewardship practitioners, Parks Canada representatives, and insurance and legal advisors — work from the constraint map to generate options that cross every boundary the map exposed.
Options that emerge from this configuration include: a national certification curriculum that the provincial ministries help author rather than receive, so that recognition is built into the design rather than sought after the fact. A shared liability framework that assigns and underwrites risk rather than leaving it undefined and therefore unactionable — the specific mechanism that has paralyzed adoption despite genuine broad agreement that prescribed fire is beneficial. A governance model that embeds Indigenous-led fire stewardship as a co-equal design authority rather than a consultee, so that the knowledge systems on which the CPFTP is explicitly built are reflected in the legal and institutional architecture that governs implementation. A cross-hub coordination mechanism ensuring that a burn successfully completed and documented in British Columbia informs the approval process in Alberta rather than each hub independently building a case from the beginning.
As in the NESDIS engagement, the options that matter most are the ones that only appear when the people who own the constraints generate them together. The provincial liability officer who understands exactly what their ministry needs before it can sign an authorization is the same person who, in a Diverge session, can sketch the liability framework that would meet that requirement. That insight is not available in sequential bilateral consultation.
Converge forces the trade-offs and produces a 30/60/90-day plan with named owners. The hard trade-off is liability, and it is the reason polite agreement has not been sufficient. Every actor agrees prescribed fire reduces catastrophic wildfire risk. No office wants to be the signatory on an authorization if a burn escapes. A convening can restate that agreement indefinitely. Converge resolves it by putting the provincial official who owns the liability, the insurer who can price and assign it, and the practitioners who will carry it in one room with a structured process that does not adjourn until risk is assigned and underwritten rather than avoided.
The NESDIS engagement broke an analogous operational deadlock by empowering a single accountable program manager, backed by a community-of-practice that the participants had co-designed and committed to operate. The prescribed-fire challenge requires the same structure applied to a different institutional terrain: a recognized national standard, an owned and underwritten liability pathway, and a named accountable team whose mandate is to execute the first sanctioned burns of the next fire season under a framework that provinces have formally agreed to recognize.
In the first thirty days, the provinces and CPFTP program leads agree on what certification they will recognize and on a liability-and-insurance pathway. By sixty days, Indigenous stewardship authority and the cross-hub coordination model are settled. By ninety days, the first practitioners are cleared to burn under a nationally recognized standard. The output is not a recommendation for leadership to consider later. It is the thing itself.
The village that must be in the room:
| Stakeholder | Role in the problem | Why their absence stalls the solution |
|---|---|---|
| UBCO program leads (Dr. Mathieu Bourbonnais) | Hold the training program, curriculum, and regional hubs | Without them there is no certification to standardize and no hub architecture to coordinate across. |
| Provincial forestry and wildfire ministries | Own Crown-land liability and the power of regulatory recognition | Absent, certification has no legal force and practitioners trained under the program cannot burn, regardless of competence. |
| Parks Canada | Manages federal lands and operates its own prescribed burn programs | Without it, federal and provincial standards diverge and practitioners face different authorization requirements on adjacent land. |
| Indigenous fire-stewardship practitioners | Hold the fire knowledge and territorial authority on which the program is explicitly built | Their absence reduces integration to nominal status and forfeits the strongest ecological knowledge base available. |
| Insurers and liability advisors | Price and assign the risk that currently paralyzes every other actor | Without a workable underwriting model, liability fear blocks adoption by every actor simultaneously, regardless of intent. |
| Municipal and rural land managers | Approve and host burns at the operational level | Absent, no plan reaches an actual sanctioned burn regardless of what the provincial and national frameworks authorize in principle. |
None of this displaces what the Foundation already does well. The convenings, the expert review panels, the grantee gatherings remain the right tools for selecting science, building relationships, and creating high-level alignment on what the problems are and why they matter. The decision-forcing process described here is a complement, brought in at the point where coordination — not analysis — has become the binding constraint. It is the instrument for the second job, used when the first job is done and the work has reached the edge of execution.
There is a simple self-test for when that point has arrived. Look across successive grant cycles and convenings: if the same coordination questions keep reappearing on the agenda — the same unresolved questions about who carries liability, who owns the regulatory pathway, who commits to the offtake, who holds the cross-program data standard — that recurrence is the signal. It points not to any shortfall in the work, but to the natural boundary of the format being used. If, on the other hand, those coordination questions are being resolved and ticked off the agenda, replaced by new ones that reflect genuine forward progress, no new tool is required and the existing process is doing its job.
Applied to the present portfolio, the test is not hard to run. The microbiome cohort’s translational walls, the prescribed-fire liability question, the homegrown offtake gap, the conservation governance question, the diagnostic deployment alignment — these are not puzzles that more analysis will dissolve. They are the coordination questions a funder encounters whenever it pushes science to the edge of deployment. Their recurrence across health, conservation, and agriculture is itself the evidence that the binding constraint has shifted from knowing to deciding.
The distinction matters because it changes what the Foundation should expect from each tool it uses. Asking a grantee convening to resolve the question of which province will recognize the CPFTP certification is asking the format to do something it is not designed to do. The convening can surface the question, name the parties, and create the conditions under which a more targeted process becomes productive. It cannot replace that process. The question of where the first tool hands off to the second is the operational question the recurrence test is built to answer.
One feature of the Foundation’s current portfolio makes this transition unusually tractable. In each of the eight initiatives, the constraint owners are known by name. Marcel van de Wouw holds the microbiome cohort gates. Dr. Mathieu Bourbonnais holds the prescribed fire training architecture. The provincial liability officers who must sign a Crown-land authorization are named officials in named ministries. The grocery buyers who must commit to an offtake agreement are not abstractions. The clarity of the constraint map is itself a product of the Foundation’s rigorous program management — and it means that the village the decision-forcing process needs to convene is already visible. What remains is to get that village into a room structured to force the trade-offs that open questions represent.
The Weston Family Foundation has already supplied the two things that are hardest to supply: the capital and the science. Its boldest bets are no longer waiting on a better answer. They are waiting on a decision — on whether seventeen laboratories will move as one portfolio, whether provinces will recognize a common fire standard, whether a grocery buyer and a plant biologist will commit to the same roadmap before 2028, whether Indigenous governments and Crown land-managers will hold a shared governance plan to 2030.
Those decisions can be made. The constraint owners are known. The science is fundable. The clocks are running but they have not closed. The open question is whether the people who must make the decisions will be brought into one room — a room structured to force the trade-offs — before the window does.
Mark McCarvill is the founder of Mind Meeting Group, a Vancouver-based strategy and facilitation firm. He has led more than 100 strategic workshops across pharmaceutical, government, and not-for-profit sectors, working with seven of the global top-twelve pharmaceutical companies and facilitating the alignment of more than 3,000 leaders and stakeholders. Mind Meeting Group specializes in complex, multi-stakeholder challenges where the answer is knowable but not yet executable — and where the right process, not more analysis, is what converts strategy into committed action.